Home > Haematology > EHA 2019 > Myeloma > Chimeric antigen receptor T cell therapy in multiple myeloma

Chimeric antigen receptor T cell therapy in multiple myeloma

Presented By
Prof. Hermann Einsele, University of Würzburg, Germany
EHA 2019
Prof. Hermann Einsele (University of Würzburg, Germany) discussed CAR-T therapy in the multiple myeloma (MM) treatment pathway [1]. The take-home message of Prof. Einsele’s presentation was that CAR-T therapy be indicated in MM in the following three scenarios: (1) in patients who are not eligible for autologous transplant, CAR-T may consolidate or maintain remission; however, safety is a concern; (2) in patients who are eligible for autologous transplant there are 2 main groups who may benefit – those with adverse cytogenetics and those who progress early. In both populations, the long-term efficacy needs to be shown; and (3) heavily pre-treated patients (double penta-refractory) may also obtain some benefit, but the efficacy of CAR-T in this population must be shown with minimal residual disease (MRD)-negativity for prolonged PFS. Patients with an MRD-negative state appear to have the same prognosis, regardless of whether they have standard or high-risk ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on